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Results: The maximum doses (in EQD2) for different critical 
organs in the H&N case are presented in Table 1, along with 
doses calculated without deformable registration or 
compensation for biological dose effects. For medulla, 
deformable EQD2 values are approximately 10% less than for 
the rigid raw sum; for other organs the difference varies from 
0 to 8%.  
Conclusions: Considerations of dose to organs at risk may be 
a limiting factor for treatment planning of secondary 
malignancies at the same site. This work has shown a 
complete framework to examine re-treatment planning 
accounting for different patient positions, dose sizes and 
fractionation schemes of new and previous treatments. This 
accurate summed EQD2 distribution is helpful in seeing which 
dose tolerances are reached, and where the treatment plan 
could be modified further. 
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Purpose/Objective: Hyperthermia is still regarded as the 
most potent biological sensitizer for radiotherapy and 
chemotherapy. In addition to positive results multiple phase 
III trials, in many studies a statistical significant relationships 
between applied thermal dose and treatment effectiveness 
were found. The, prospective study of Jones et al. [1] and 
the large, retrospective study of Franckena et al. [2] are 
highly convincing and demonstrate a clear rationale for 
thermal dose escalation. These findings motivated us to 
develop a software to apply HT under objective control of an 
on-line hyperthermia treatment planning (HTP) system. 
International consensus exists that the application of HT will 
benefit strongly from on-line HTP with 3D-visualization and 
control of the heating pattern in the patient. 
Materials and Methods: A software tool called VEDO 
(Visualization tool for Electromagnetic Dosimetry and 
Optimization) was created. The inputs required are: a 3D 
segmentatio of the patient model comprising all tissues, 
target, OAR and pre-calculated electromagnetic fields. VEDO 
calculates Specific Absorption Rate (SAR) distributions and 
performs optimization using a particle swarm (PS) 
optimization algorithm. Spatial optimization weighting 
regions can be manually set. Clinically important quantifiers 
like predicted target SAR dose and maximum allowed power, 
based on SAR in critical tissues, are visualized. 
Results: 
VEDO provides an instant visualization of the SAR-distribution 
(as color wash) over the patients CT using the simulated 
electric fields and real-time measured phase and amplitude 
of the signals fed to each antenna element. Pre-treatment, 
VEDO is used by the MDs for decision making. During 
treatment, VEDO helps the operator to correlate the location 
of pain-complaints to predicted high SAR values near the 
indicated region; allowing re-optimization for reduction of 
the SAR at the indicated 'hot-spot' area. With this, complaint-
adaptive SAR steering is used to convert hotspots in re-
optimized settings, with reduced local SAR, that can directly 
be applied to the patient anatomy. In patients with head and 
neck tumors complaint adaptive SAR steering resulted in at 
least 20% increase of the SAR delivered to the target.  
Conclusions: VEDO is completely objective and quantitative, 
and can be evaluated on its effectiveness. The latter is an 
important step towards abandoning treatment optimization 
based on experience of the hyperthermia staff members. The 
simulations using the patient anatomy also provides much 
more insight as compared to experimental SAR measurements 
in homogeneous phantoms. Clinical application of VEDO 
shows that the workflow is feasible and that re-optimization 
based on patient discomfort is effective in reducing 
complaints.  
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Purpose/Objective: To determine the relationship between 
recurrence locations and pre-RT 18F-FDG PET SUV data for 
patients diagnosed with HNSCC. 
Materials and Methods: Based on a patient group of 90 
patients treated with IMRT or VMAT, a retrospective 
investigation of local variations in TCP depending on 
pretreatment 18F-FDG PET SUV through use of recurrence 
